AOD-9604 peptide: what the modified GH fragment does, and what it doesn't

AOD-9604 stands for Anti-Obesity Drug 9604. The name is a tell: it was developed as an obesity therapeutic, not a wellness peptide. Researchers working through a company called Metabolic Pharmaceuticals developed it, with Australian academic roots.

The molecule is a synthetic 16-amino-acid fragment corresponding to residues 176-191 of human growth hormone, with one modification: an extra tyrosine on the N-terminus for stability ^[1]. The formal name is Tyr-hGH177-191. Two cysteines form a disulfide bridge, giving the peptide its loop structure. Molecular weight comes in around 1,815 g/mol ^[2].

The whole design hinged on a hypothesis that turned out to be partially true: that growth hormone's fat-metabolizing activity lives in a separable region of the molecule, distinct from the parts responsible for tissue growth and insulin resistance. If you could isolate the fat-burning C-terminal piece, you'd theoretically have hGH's lipolytic effects without the cell proliferation or the diabetogenic profile that makes full growth hormone a complicated drug.

The biochemistry held up. The clinical trials, eventually, did not.

This is where the pharmacology gets specific, and where most marketing copy gets sloppy.

Full-length human growth hormone binds the growth hormone receptor and triggers IGF-1 production through the liver. That cascade drives both the therapeutic effects of GH (lean mass, recovery) and the problems (insulin resistance, edema, possible mitogenic concerns). AOD-9604 doesn't bind the GH receptor in any meaningful way. It doesn't raise IGF-1. Across the clinical program, oral glucose tolerance testing showed no negative effect on carbohydrate metabolism.

Now compare it to the secretagogue peptides: CJC-1295, ipamorelin, sermorelin. Those work by stimulating your pituitary to release more of your own growth hormone. They act upstream of the GH receptor, push IGF-1 up, and produce the full downstream GH signature. AOD-9604 sits in a completely different category: a fragment with no receptor relationship to the GH axis at all.

The mechanistic separation is real. Whether the lipolytic effect, on its own, is clinically meaningful in humans is the harder question.

The leading model is beta-3 adrenergic. Beta-3 receptors sit on adipocytes and, when activated, drive the classic lipolytic cascade: cAMP rises, protein kinase A activates, hormone-sensitive lipase phosphorylates, triglycerides hydrolyze, and fatty acids exit the fat cell for oxidation. AOD-9604 appears to upregulate beta-3 receptor expression on fat cells, particularly in obese tissue where these receptors are otherwise suppressed.

The cleanest evidence for this comes from Heffernan and colleagues, publishing in Endocrinology in 2001 ^[3]. Their team gave AOD-9604 to obese mice for fourteen days and watched body weight and fat mass drop while beta-3 mRNA climbed ^[4]. Then they ran the same experiment in beta-3 knockout mice. The chronic weight-loss effect vanished ^[5].

That's a strong genetic argument that beta-3 is doing the work.

But the story gets less tidy. In the same knockout mice, acute energy expenditure still rose when AOD-9604 was administered. So something else is happening too, a secondary mechanism, not yet characterized, that contributes to short-term metabolic activity independent of beta-3. The peptide also appears to inhibit lipogenesis, the fat-storage side of the equation, giving it a dual action in theory: more breakdown, less storage.

That's the model. Most of it was built in rodents.

In genetically obese rats and mice, AOD-9604 reliably produced fat loss without the insulin resistance that hGH causes. Ng and colleagues reported this in obese Zucker rats in Hormone Research in 2000 ^[6]. The pattern replicated across several rodent studies through the early 2000s: lipolysis up, body fat down, glucose handling preserved.

The animal package was clean enough to justify human trials. That's a low bar, but AOD-9604 cleared it.

Where the preclinical data thins out is in mechanism specifics outside of rodents. There are no primate studies of consequence in the public literature. Pharmacokinetic work in pigs suggested the peptide degrades through proteolytic mechanisms, which is what you'd expect for a small peptide moving through plasma: short half-life, proteolytic clearance.

For the wellness market's claims about dramatic visceral fat reduction, the foundation is genetically obese mice and a handful of metabolic readouts. It's a foundation. It's not a clinical case.

Between roughly 2001 and 2007, Metabolic Pharmaceuticals ran several human clinical trials of AOD-9604, enrolling over 900 participants in total. Two intravenous pilot studies. Two oral pilot studies. Two Phase 2b oral trials. The bulk of the program was in clinically obese adults.

The signal that drove enthusiasm came from the first Phase 2b trial, reported around 2004. Oral doses in the program ranged from 1 mg up to 30 mg per day ^[7]. That trial had no formal diet and exercise programme. All five dose groups lost more weight than placebo over twelve weeks, and the best group was 1 mg: higher doses didn't do better. Even 1 mg fell short of statistical significance on the main analysis (p=0.1), reaching it only in the women ^[8].

So the signal was weaker than it is often described. By the developer's own account, the best dose missed significance.

Then came the key Phase 2b trial, called OPTIONS. 536 subjects. A four-week diet-and-exercise run-in, then twenty-four weeks of treatment at 0.25, 0.5 or 1 mg. It was powered to detect 1.8 kg more weight loss than placebo at twelve weeks ^[9].

It failed.

The drug did not separate from placebo on the primary endpoint. Weight loss beyond placebo was under 1 kg in every dose group at twelve and at twenty-four weeks. The trial had layered a diet-and-exercise programme onto both arms, which may have pushed the placebo response up and obscured any drug effect. That's the explanation Metabolic Pharmaceuticals offered. But the failure was the failure. The company ended development for obesity on 21 February 2007 ^[9]. The obesity programme ended after Phase 2b, before any Phase 3 trial, so it never reached an application for approval ^[9]. The key Phase 2b results were never submitted to a peer-reviewed journal, which is itself worth noting; the documented failure lives in the company's stock-exchange announcements, which it also filed with the SEC ^[9], and a 2013 review by Misra in Current Cardiology Reviews ^[10].

No Phase 3 program ever ran. AOD-9604 has never been tested in a registrational trial.

After obesity development collapsed, a different research thread opened. In February 2013, Lateral Pharma (which held rights to the molecule) released animal data on AOD-9604 in a rabbit osteoarthritis model ^[11]. Intra-articular injections, given alone or combined with hyaluronic acid, appeared to enhance cartilage repair. The combination outperformed either agent on its own. No adverse joint reactions were reported.

This was a corporate ASX disclosure, not a peer-reviewed publication. The work has been associated in some accounts with CSIRO-affiliated researchers, though the published trail is thin.

The data are interesting enough to justify continued investigation. They're not nearly enough to support clinical claims about human osteoarthritis. No human OA trial of AOD-9604 has been conducted. Every joint-repair claim circulating in the peptide marketing space rests on rabbits.

This one needs care, because it's the most misused regulatory fact about AOD-9604.

In June 2012, AOD-9604 received self-affirmed GRAS status, Generally Recognized As Safe, for use as a dietary supplement ingredient ^[12]. The wellness industry frequently translates this as "FDA-approved" or "FDA-recognized as safe and effective." Neither is accurate.

GRAS is a food-additive framework. It addresses safety only, not efficacy. Self-affirmed GRAS, specifically, means the sponsor assembled a safety dossier and concluded the ingredient is safe. The FDA doesn't actively endorse self-affirmed GRAS determinations the way it endorses drug approvals or even GRAS notifications it has formally reviewed.

What GRAS doesn't do: it doesn't approve AOD-9604 as a drug, doesn't permit therapeutic claims, and doesn't authorize prescription compounding. It's a designation built for food ingredients, repurposed by marketers as a credibility signal it was never designed to carry.

For prescribing, AOD-9604 is not FDA-approved for any indication. No NDA, no BLA, no monograph. It doesn't appear on the FDA's 503B Bulks List ^[13], and it is not on the 503A positive list either.

Its 503A history is specific, and vendors describe it loosely. FDA placed AOD-9604 in Category 2 of the interim 503A policy in September 2023 — the bucket for substances the agency says present significant safety risks. In September 2024 it was pulled back out, together with CJC-1295, ipamorelin acetate, thymosin alpha-1 and selank, and referred to the Pharmacy Compounding Advisory Committee.

The committee reviewed AOD-9604 at its December 4, 2024 meeting ^[14], and FDA has not added it to the 503A Bulks List since. None of the five was on the committee's July 23-24, 2026 agenda, which took up seven of the twelve peptides that came out of Category 2 in April 2026 — a different group. So the accurate status is neither prohibited nor permitted, with no scheduled date for a decision and no rulemaking under way. The list-by-list breakdown tracks where each group sits, and pharmacies dispensing AOD-9604 are operating in that gap.

Across the roughly 925 humans who took AOD-9604 in the Metabolic Pharmaceuticals program, the safety profile was, by all available accounts, clean. No serious adverse events. Tolerability comparable to placebo in randomized comparisons. Glucose handling preserved. IGF-1 unchanged. No weight rebound documented in the trials that did show weight loss.

That's a genuinely reassuring short-term signature.

What we don't have: any human safety data beyond roughly 24 weeks. No pediatric data. No pregnancy or lactation data. No formal drug-drug interaction studies. No post-marketing pharmacovigilance program of the kind that exists for approved drugs, because AOD-9604 has never been approved.

The FDA's FAERS database, which collects spontaneous adverse-event reports, contains entries associated with AOD-9604, including reports of chronic kidney disease and entries tagged "drug ineffective." FAERS data are uncontrolled, unverified, and can't establish causation. The "drug ineffective" cluster is consistent with what we already know from the Phase 2b failure. The kidney signal needs context that doesn't yet exist in the published literature. It's worth flagging without overclaiming.

Short answer on safety: clean within the windows tested, unknown outside them.

This is where the gap between data and marketing widens most visibly.

Claims commonly made about AOD-9604 that the human evidence doesn't support: dramatic visceral fat reduction, rapid body recomposition, joint regeneration in humans, and any cosmetic outcome on the timeframes typically promised. The strongest human result on record is about 2 kg of placebo-adjusted weight loss over twelve weeks at the 1 mg oral dose, and that result did not replicate in the longer, larger, definitive trial.

The osteoarthritis claims rest on rabbits.

The "increases growth hormone" claim, which appears in some marketing, is mechanistically wrong. AOD-9604 has no known activity on the GH-releasing pathway.

The "burns fat without affecting IGF-1 or blood sugar" claim is the one that's actually well-supported. It just happens to be paired with the equally well-supported observation that the fat-burning effect, in adequately powered human trials, was not large enough to register.

AOD-9604 is one of the more scientifically coherent peptides in the wellness space, and one of the more clinically disappointing. The mechanistic story is real. The receptor-level separation from full hGH is real. The short-term human safety record is real.

What's also real: the only adequately powered human trial failed. The key data were never peer-reviewed. The osteoarthritis pivot rests on animal work. The GRAS designation is being used to imply regulatory standing it doesn't confer. Long-term safety is uncharacterized.

A reasonable researcher considering AOD-9604 might do so understanding that the molecule sits in a particular position: interesting enough to keep studying, safe enough in the short term that the early trials cleared without incident, and yet, when actually tested at adequate power for the indication it was designed for, unable to produce a clinically meaningful weight-loss effect.

The honest read of the data goes like this. If you want a peptide with a clear human efficacy signal for body weight, AOD-9604 is not it. If you want a peptide with a clean mechanistic rationale, a non-trivial clinical safety record, and an unresolved efficacy question, that's a more accurate description of what's actually on the table.

What remains genuinely unknown: whether intermittent dosing, different routes, or specific patient subsets might produce a different result than the 2007 Phase 2b. Whether the rabbit OA data translate to humans at all. Whether the FAERS renal signal reflects anything real. Whether long-term use carries risks not visible in 24-week windows.

These are the questions a Phase 3 program might have answered. There was no Phase 3 program. There's unlikely to be one. The molecule has migrated, instead, into a market that doesn't require those answers, which is the part worth thinking carefully about before deciding what to do with the information.

Counted from PubMed and ClinicalTrials.gov on October 9, 2026. A study counts only if participants were given AOD-9604. How we count, and the same figures for every peptide we cover.

Neither registry lists a trial in which people were given AOD-9604.